Altogether, the infusion product for this patient demonstrated superior quality due to factors such as CD8+ TIL predominance, tumor-specific reactivity, the presence of stem-like CD39negCD69negCD8+ T cells, and a strong overlap of TCRβ sequences between infusion product and periphery, likely contributing to durable TIL response. The gene discussed is CD8A; the disease is neoplasm.